Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 3/20 | 0.62 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.62 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.62 |
| ▸ | POLA1 | P09884 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.48 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.48 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.42 |
| ▸ | ALB | P02768 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.42 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.42 |
| ▸ | POLG | P54098 | 2/20 | 0.40 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15329080 | 0.91 | PDE3A (0.61) | PDE3APDE4DSLC29A1POLA1LMNA | |
| SCHEMBL31657621 | 0.89 | PDE3A (0.61) | PDE3APDE4DSLC29A1POLA1LMNA | |
| SCHEMBL20943434 | 0.88 | PDE3A (0.56) | PDE3APDE4DSLC29A1POLA1LMNA | |
| SCHEMBL31552872 | 0.86 | PDE3A (0.54) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Phosphoric Acid SCHEMBL20769295 | 0.85 | PDE3A (0.73) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Phosphoric Acid SCHEMBL4576320 | 0.85 | PDE3A (0.73) | PDE3APDE4DSLC29A1POLA1LMNA | |
| SCHEMBL32672458 | 0.84 | PDE3A (0.62) | PDE3APDE4DSLC29A1POLA1LMNA | |
| SCHEMBL15316783 | 0.82 | PDE3A (0.80) | PDE3APDE4DSLC29A1POLA1LMNA | |
| SCHEMBL232223 | 0.82 | PDE3A (0.80) | PDE3APDE4DSLC29A1POLA1LMNA | |
| SCHEMBL15329232 | 0.82 | PDE3A (0.50) | PDE3APDE4DSLC29A1POLA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 912 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107341-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION | Vir Biotechnology, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4745239-A1 | CFB INHIBITOR COMPOSITION AND USE THEREOF | Rigerna Therapeutics Co., Ltd. (CN) | 2026-05-20 | — | — | EP | claimed |
| EP-4714500-A2 | HEPATITIS B VIRUS (HBV) DSRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| EP-3837366-B1 | HEPATITIS B VIRUS (HBV) DSRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS INC (US) | 2026-02-18 | — | — | EP | claimed |
| US-20260022161-A1 | COMBINATION HBV THERAPY | VIR BIOTECHNOLOGY INC (US) | 2026-01-22 | — | — | US | claimed |
| EP-4656656-A2 | COMBINATION HBV THERAPY | Humabs BioMed SA (CH) | 2025-12-03 | — | — | EP | claimed |
| US-20250320497-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION AND HBV-ASSOCIATED DISEASES | VIR BIOTECHNOLOGY INC (US) | 2025-10-16 | — | — | US | claimed |
| EP-4285929-B1 | COMBINATION HBV THERAPY | HUMABS BIOMED SA (CH) | 2025-10-08 | — | — | EP | claimed |
| US-20250302951-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS D VIRUS (HDV) INFECTION AND ASSOCIATED DISEASES | Vir Biotechnology, Inc. | 2025-10-02 | — | — | US | claimed |
| US-20250304967-A1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2025-10-02 | — | — | US | claimed |
| US-10933081-B2 | Myostatin iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-03-02 | — | — | US | claimed |
| WO-2020232024-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION | Vir Biotechnology, Inc. (US) | 2020-11-19 | — | — | WO | claimed |
| EP-3728593-A1 | HIGH MOBILITY GROUP BOX-1 (HMGB1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2020-10-28 | — | — | EP | claimed |
| US-20200308588-A1 | HIGH MOBILITY GROUP BOX-1 (HMGB1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-10-01 | — | — | US | claimed |
| WO-2020132346-A1 | COMBINATION HBV THERAPY | Vir Biotechnology, Inc. (US) | 2020-06-25 | — | — | WO | claimed |
| US-20200138847-A1 | MYOSTATIN IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2020-05-07 | — | — | US | claimed |
| US-10640770-B2 | Hepatitis D virus (HDV) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-05-05 | — | — | US | claimed |
| EP-3146049-B1 | ANGIOTENSINOGEN (AGT) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS INC (US) | 2020-02-26 | — | — | EP | claimed |
| WO-2020036862-A1 | HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-02-20 | — | — | WO | claimed |
| US-10478500-B2 | Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-11-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022161-A1 | COMBINATION HBV THERAPY | NSUN2, RNMT, RNGTT | PDE3A 865/4885PDE4D 1541/4885SLC29A1 40/4885 |
| US-20250304967-A1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | HSD17B13, HSD17B3, HSD17B1 | PDE3A 1292/4885PDE4D 1602/4885SLC29A1 2419/4885 |
| US-20250302951-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS D VIRUS (HDV) INFECTION AND ASSOCIATED DISEASES | DNTT, HAVCR2, POLRMT | PDE3A 2782/4885PDE4D 1382/4885SLC29A1 208/4885 |
| US-10478500-B2 | Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression | HAO1, HAO2, ACOX1 | PDE3A 3280/4885PDE4D 3491/4885SLC29A1 992/4885 |
| US-10640770-B2 | Hepatitis D virus (HDV) iRNA compositions and methods of use thereof | HAVCR2, EIF2AK2, CDV3 | PDE3A 4384/4885PDE4D 2839/4885SLC29A1 1399/4885 |
| US-20250320497-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION AND HBV-ASSOCIATED DISEASES | IFNAR1, IFNG, HAVCR2 | PDE3A 1301/4885PDE4D 2096/4885SLC29A1 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.